Lecanemab: turning point, or status quo? An ethics perspective
Author:
- 21 March 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (9) , e71-e72
Abstract
Timothy Daly; Lecanemab: turning point, or status quo? An ethics perspective, Brain, , awad094, https://doi.org/10.1093/brain/awad094Keywords
This publication has 8 references indexed in Scilit:
- An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?Brain, 2023
- Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration2023
- Expectations and clinical meaningfulness of randomized controlled trialsAlzheimer's & Dementia, 2023
- Lecanemab for Alzheimer’s diseaseBMJ, 2022
- An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s DiseaseAJOB Neuroscience, 2022
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsNature Reviews Drug Discovery, 2022
- Alzheimer’s disease: where next for anti-amyloid therapies?Brain, 2017
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992